Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,941 matching trials from the live ClinicalTrials.gov search.
Conditions
Fibromyalgia Syndrome
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
35
States / cities
Mobile, Alabama • Mesa, Arizona • Peoria, Arizona + 32 more
Conditions
Cerebral Palsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Musculoskeletal Pain
Interventions
Virtual Reality Augmented remote rehabilitation
Other
Lead sponsor
XRHealth USA Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Brookline, Massachusetts
Conditions
Chronic Low Back Pain, Musculoskeletal Pain
Interventions
intermittent theta burst stimulation, LoveYourBrain Yoga Program
Device · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
22 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Chicago, Illinois • Hines, Illinois
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Comparative Autoantibody and Immunologic Cell Marker Study

NCT02422875
Conditions
Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Duchenne Muscular Dystrophy
Interventions
Edasalonexent
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
4 Years to 12 Years · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Sacramento, California • Atlanta, Georgia • Iowa City, Iowa + 11 more
Conditions
Myotonic Dystrophy Type 1
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Stanford, California
Conditions
Temporomandibular Joint and Muscle Disorder
Interventions
Biobehavioral, Active Coping/Attention Intervention
Behavioral
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Arlington, Texas
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Gluteus Maximus Recruitment

NCT02042937
Conditions
Muscular Weakness
Interventions
Exercise
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 36 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
MSDs, Muscle Pain
Interventions
stretching exercises
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
No Longer Available No phase listed Expanded access

Extension Study of Drisapersen in DMD Subjects

NCT02636686
Conditions
Duchenne Muscular Dystrophy
Interventions
Drisapersen
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Arthrogryposis, Craniofacial Abnormalities
Interventions
Lactate, Glucose, and Adenosine Triphosphate Blood Levels, Physiological Stress Test, Functional Enquiry Form, Strength, Joint ROM, Girth and Length Measurements, Study Physical Examination, Observational Gait Analysis, Mental Health Interview
Other · Procedure
Lead sponsor
Freeman-Sheldon Research Group, Inc.
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Buckhannon, West Virginia
Recruiting No phase listed Observational Accepts healthy volunteers

Endogenous Pain Inhibition Deficiency in Chronic TMD Pain

NCT06617494
Conditions
Chronic Temporomandibular Disorders (TMD)
Interventions
Pain modulation testing
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 74 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Duchenne Muscular Dystrophy
Interventions
WVE-210201 (suvodirsen), Placebo
Drug
Lead sponsor
Wave Life Sciences USA, Inc.
Industry
Eligibility
5 Years to 12 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
New Haven, Connecticut • Atlanta, Georgia • Kansas City, Kansas + 3 more
Conditions
Juvenile Idiopathic Arthritis (JIA), Fibromyalgia, Lupus, Scoliosis, Pectus Excavatum, Chronic Pain, Musculoskeletal Pain
Interventions
Not applicable- observational study
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
14 Years to 26 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed No phase listed Observational

Myotubular Myopathy Event Study

NCT01840657
Conditions
X-linked Myotubular Myopathy
Interventions
Not listed
Lead sponsor
Cure CMD
Other
Eligibility
Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Torrance, California
Conditions
Duchenne Muscular Dystrophy
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Years to 21 Years · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Terminated Phase 1Phase 2 Interventional Results available

Evaluating Muscle Weakness Improvement With Lorcaserin in ICU

NCT02523690
Conditions
Muscle Weakness, Sepsis
Interventions
Lorcaserin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Duchenne Muscular Dystrophy
Interventions
Gentamicin infusions twice a week for six months
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
5 Years to 20 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • Kansas City, Kansas • Columbus, Ohio
Conditions
Freeman-Sheldon Syndrome, Arthrogryposis Distal Type 2A, Whistling Face Syndrome, Craniocarpotarsal Dysplasia, Craniocarpotarsal Dystrophy, Freeman-Sheldon Syndrome Variant, Sheldon-Hall Syndrome, Arthrogryposis Distal Type 2B, Gordon Syndrome, Arthrogryposis Distal Type 3, Arthrogryposis Distal Type 1, Arthrogryposis, Distal, Type 1A, Arthrogryposis Distal Type 1B, Arthrogryposis, Distal, Craniofacial Abnormalities, Arthrogryposis
Interventions
PTSD Checklist-Civilian (PCL-C), Modified Flanagan Quality of Life Scale, Center for Epidemiologic Studies Depression Scale (CES-D), Functional Enquiry (or Review of Systems) Form, Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire, FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI), Medical Records Review
Other
Lead sponsor
Freeman-Sheldon Research Group, Inc.
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Buckhannon, West Virginia
Conditions
Musculoskeletal Pain
Interventions
Emotional Awareness and Expression Therapy
Behavioral
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
60 Years to 95 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Frailty, Weakness, Muscle, Multiple Chronic Conditions
Interventions
Beta-hydroxymethyl butyrate supplement, Vitamin D supplement, Matching Beta-hydroxymethyl butyrate supplement without Vitamin D
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb Girdle Muscular Dystrophy
Interventions
Coenzyme Q10 and Lisinopril
Drug
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
8 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Charlotte, North Carolina + 2 more
Completed Phase 3 Interventional Results available

Safety Study of SPARC1104

NCT01797185
Conditions
Spasticity
Interventions
SPARC1104 modified dose regimen I, SPARC1104 modified dose regimen II, SPARC1104 modified dose regimen III
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years to 90 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
51
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 47 more